Safety and efficacy of plamotamab in the treatment of non-Hodgkin lymphoma subtypes

0 Views

07/09/23

Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, discusses some findings from a Phase I trial investigating the safety and efficacy of plamotamab, an anti-CD20 anti-CD3 bispecific antibody, in the treatment of patients with non-Hodgkin lymphoma (NHL). Dr Phillips highlights some of the results from this study, which found that plamotamab was effective in patients with various sub-types of NHL, including multiple relapsed diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). Dr Phillips also mentions that in some patients who have received chimeric antigen receptor T-cell (CAR-T) therapy, there have been good responses to plamotamab, and that further safety and efficacy data on step-up dosing regimens is needed. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.